B+
Bull case
25%
Probability
Target price
$82.20
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
GEHC
GE HealthcareANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$74.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+77.6
Score
AI commentary
The evidence mix is moderately positive but increasingly balanced: the primary Q2 release supports strong orders, backlog, and reaffirmed guidance, while the company-announced August 31 Photonova Spectra CE Mark adds a dated product-access catalyst. PCS weakness, CFO transition risk, cost pressure, and uncertain commercial follow-through remain unresolved. Stored Zacks context reports shares up about 3.6% since the last earnings report but underperforming the S&P 500; trusted analyst target and estimate-change data are incomplete. Social coverage is unavailable, so confidence should remain monitoring-oriented.
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-12-04eventQ2 2026 earnings beat with guidance reaffirmedMedium impact
GE HealthCare reported 5.7% revenue growth, 3.5% organic growth, adjusted EPS of $1.13 versus $1.06 a year earlier, and reaffirmed 2026 guidance. The primary SEC-filed release also reported 11.1% organic orders growth and a record $23.9 billion backlog [#SEC-8K-2026-07-29].
2026-12-04catalystPCS recovery and leadership-transition executionMedium impact
Patient Care Solutions declined 13.3% year over year, while the company is reviewing strategic options and has begun a permanent CFO search. The CFO transition was formally disclosed in the July 2026 filing [#SEC-8K-2026-07-23]. A later 8-K excerpt also references a $550,000 sign-on payment for Mr. Grogan, which is a transition-monitoring item rather than evidence of operating performance [#8-K-2026-08-18].
2027-09-05catalystPhotonova Spectra CE Mark expands international accessHigh impact
GE HealthCare announced on August 31, 2026 that Photonova Spectra achieved CE Mark after U.S. FDA 510(k) clearance and Japanese regulatory approval, supporting expanded research and clinical adoption in CE Mark-observing countries. The company described the milestone as part of a portfolio of transformational products expected to drive 1-2% revenue growth, but near-term revenue realization remains unquantified [#IR-2026-08-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology